* = Guardant360 Liquid CDx is under review with notified Body / EMA.
Product availability may vary depending on country / region.
1. Forouzmand E, He Y, Gittelman R, et al. A novel methylation-based classifier to identify cancer signal of origin using blood based testing. Abstract 6365. Cancer Res. 2025;85(8 suppl 1):6365. doi:10.1158/1538-7445.AM2025-6365; 2. Forouzmand E, He Y, Greenwald WY, et al. Epigenomic-based classifier for cancer signal of origin in liquid biopsy for cancer of unknown primary. J Clin Oncol. 2025;43(16 suppl):3073. doi:10.1200/JCO.2025.43.16_suppl.3073.; 3. Valouev A, Tian W, Singh K, et al. Non-invasive cell free DNA (cfDNA) methylation profiling for accurate proportional quantification of lung cancer subtypes. Abstract 1142. Cancer Res. 2025;85(8 suppl 1):1142. doi:10.1158/1538-7445.AM2025-1142. 4. Tolkunov D, Weipert C, Wienke S, et al. Liquid based methylation profiling for quantification of breast cancer subtypes. Abstract 3247. Cancer Res. 2025;85(8 suppl 1):3247. doi:10.1158/1538-7445.AM2025-3247; 5. Gross AM, Quinn K, Bucheit L, et al. Development and characterization of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA. Abstract 733. Cancer Res. 2025;85(8 suppl 1):733. doi:10.1158/1538-7445.AM2025-733.
Home Oncology Portfolio Partnerships European Policy
Molecular Lung and Breast Subtyping:
Assesses proportion of adenocarcinoma,
squamous cell carcinoma, and SCLC or HR,
HER2 and TNBC subtypes to supplement
histological assessment.3,4
Likelihood patient is biomarker negative:
confirm the absence or FDA-approved
genomic biomarkers in Lung and CRC
for ctDNA-negative results.5
Molecular Tumor Typing:
Utilize epigenomic
signatures to help identify tissue of origin.1,2